Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results In Its Third Phase 3 Clinical Trial In Insomnia
Tue, 21 Nov 2006 08:00 AM EST
... Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced positive results from the company's Phase 3 clinical trial evaluating SILENOR(TM) (doxepin HCl) in elderly patients with primary sleep maintenance insomnia. [click link for full article] ...
Related Topics
- Clinical Trials
- Insomnia
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Clinical Growth Charts
- Tb
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Primary Insomnia
- Patient Issues
- Hypnotherapy
- Epidemiology
- Clinical Laboratory Improvement Amendments
- Depression

Not Signed In -

